Notably, blockade of these cells in the murine mucosa reduces tumor incidence and significantly upregulates CCL2 and CCR2 expression in CAC (235), suggesting that although CD11b+Gr1+ MDSCs effectively attenuate inflammation and ameliorate IBD, they may concurrently possess tumorigenic potential. Here, ITGAM is linked to inflammatory bowel disease.